Direct cardiac effects of dobutamine, dopamine, epinephrine, and levosimendan in isolated septic rat hearts

Shock

Volumn 34, Issue 3, 2010, Pages 269-274

  Zausig, York A ^a   Geilfus, Diana ^a   Missler, Goetz ^a   Sinner, Barbara ^a   Graf, Bernhard M ^a   Zink, Wolfgang ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

catecholamine; dobutamine; dopamine; epinephrine; isolated heart; levosimendan; Sepsis

Indexed keywords

ADRENALIN; DOBUTAMINE; DOPAMINE; LEVOSIMENDAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CHRONOTROPISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART PERFORMANCE; INOTROPISM; ISOLATED HEART; MALE; MECHANICS; NONHUMAN; RAT; SEPSIS;

ANIMALS; CARDIOTONIC AGENTS; DOBUTAMINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPINEPHRINE; HEART; HEART RATE; HYDRAZONES; MALE; MODELS, ANIMAL; MYOCARDIUM; OXYGEN CONSUMPTION; PERITONITIS; PYRIDAZINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; SHOCK, SEPTIC; THERAPEUTIC EQUIVALENCY;

EID: 77955976795     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181cd877b     Document Type: Article

References (35)

1. Parrillo JE: Myocardial depression during septic shock in humans. Crit Care Med 18:1183-1184, 1990.
2. Fernandes CJ Jr, Akamine N, Knobel E: Myocardial depression in sepsis. Shock 30(suppl 1):14-17, 2008.
3. Krishnagopalan S, Kumar A, Parrillo JE: Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 8:376-388, 2002.
4. Merx MW, Weber C: Sepsis and the heart. Circulation 116:793-802, 2007.
5. Muller-Werdan U, Buerke M, Ebelt H, Heinroth KM, Herklotz A, Loppnow H, Russ M, Schlegel F, Schlitt A, Schmidt HB, et al.: Septic cardiomyopathyVa not yet discovered cardiomyopathy? Exp Clin Cardiol 11:226-236, 2006.
6. Hayes MA, Timmins AC, Yau EH, Palazzo M, Watson D, Hinds CJ: Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome. Crit Care Med 25:926-936, 1997.
7. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17-60, 2008.
8. Reinhart K, Brunkhorst F, Bone H, Gerlach H, Grundling M, Kreymann G, Kujath P, Marggraf G, Mayer K, Meier-Hellmann A, et al.: Diagnosis and therapy of sepsis: guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine. Anaesthesist 55(suppl 1):43-56, 2006.
9. Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE: Vasopressor and ino-tropic support in septic shock: an evidence-based review. Crit Care Med 32: S455-S465, 2004.
10. Aghajani E, Korvald C, Nordhaug D, Revhaug A, Myrmel T: Increased oxygen cost of contractility in the endotoxemic porcine left ventricle. Scand Cardiovasc J 38:187-192, 2004.
11. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH: Cecal ligation and puncture. Shock 24(suppl 1):52-57, 2005.
12. Freise H, Bruckner UB, Spiegel HU: Animal models of sepsis. J Invest Surg 14:195-212, 2001.
13. Zausig YA, Busse H, Lunz D, Sinner B, Zink W, Graf BM: Cardiac effects of induction agents in the septic rat heart. Crit Care 13:R144, 2009.
14. 2+-homeostasis of skeletal muscle fibers during sepsis. Crit Care Med 36:1559-1563, 2008.
15. Zausig YA, Stowe DF, Zink W, Grube C, Martin E, Graf BM: A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts. Anesth Analg 102:1646-1652, 2006.
16. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P: Experimental models of sepsis and their clinical relevance. Shock 30(suppl 1):53-59, 2008.
17. Tang C, Liu MS: Initial externalization followed by internalization of beta-adrenergic receptors in rat heart during sepsis. Am J Physiol 270:R254-R263, 1996.
18. Deitch EA: Animal models of sepsis and shock: a review and lessons learned. Shock 9:1-11, 1998.
19. Graf BM, Abraham I, Eberbach N, Kunst G, Stowe DF, Martin E: Differences in cardiotoxicity of bupivacaine and ropivacaine are the result of physico-chemical and stereoselective properties. Anesthesiology 96:1427-1434, 2002.
20. Dubin A, Murias G, Sottile JP, Pozo MO, Baran M, Edul VS, Canales HS, Etcheverry G, Maskin B, Estenssoro E: Effects of levosimendan and dobu-tamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 33:485-494, 2007.
21. Levy B, Mansart A, Bollaert PE, Franck P, Mallie JP: Effects of epinephrine and norepinephrine on hemodynamics, oxidative metabolism, and organ energetics in endotoxemic rats. Intensive Care Med 29:292-300, 2003.
22. Matsuda N, Hattori Y, Akaishi Y, Suzuki Y, Kemmotsu O, Gando S: Impairment of cardiac beta-adrenoceptor cellular signaling by decreased expression of G(s alpha) in septic rabbits. Anesthesiology 93:1465-1473, 2000.
23. Rudiger A, Singer M: Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 35:1599-1608, 2007.
24. Abraham E, Singer M: Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 35:2408-2416, 2007.
25. Trager K, DeBacker D, Radermacher P: Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 9:271-278, 2003.
26. McDonough KH, Causey KM: Effects of sepsis on recovery of the heart from 50 min ischemia. Shock 1:432-437, 1994.
27. Fernandes D, Assreuy J: Nitric oxide and vascular reactivity in sepsis. Shock 30(suppl 1):10-13, 2008.
28. McDonough KH, Smith T, Patel K, Quinn M: Myocardial dysfunction in the septic rat heart: role of nitric oxide. Shock 10:371-376, 1998.
29. Barth E, Albuszies G, Baumgart K, Matejovic M, Wachter U, Vogt J, Radermacher P, Calzia E: Glucose metabolism and catecholamines. Crit Care Med 35:S508-S518, 2007.
30. Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, Troche G, Ricard JD, Nitenberg G, Papazian L, et al.: Norepinephrine plus dobuta-mine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676-684, 2007.
31. Barraud D, Faivre V, Damy T, Welschbillig S, Gayat E, Heymes C, Payen D, Shah AM, Mebazaa A: Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med 35:1376-1382, 2007.
32. Behrends M, Peters J: The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med 29:1802-1807, 2003.
33. Kaheinen P, Pollesello P, Levijoki J, Haikala H: Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 43:555-561, 2004.
34. Cunha-Goncalves D, Perez-de-Sa V, Dahm P, Grins E, Thorne J, Blomquist S: Cardiovascular effects of levosimendan in the early stages of endotoxemia. Shock 28:71-77, 2007.
35. Rump AF, Acar D, Klaus W: A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br J Pharmacol 112:757-762, 1994.